CDMO Dossier

PROCESS SCOPE · VERIFY THE MATCH

How to confirm a CDMO supports your protein process

General biologics, cell-culture, or network-wide wording is not enough to establish that a named US site supports your molecule, expression host, commercial phase, or unconjugated mAb scope.

Lonza Portsmouth

custom production of mammalian biopharmaceuticals; GS-system for monoclonal antibodies and recombinant proteinsScope limits · Source ↗

FUJIFILM Holly Springs

Commercial-scale mammalian cell culture; monoclonal antibodies.Vendor announcement July 8, 2026; product-specific qualification still required. Source & date

Samsung Biologics Rockville

Protein-specific scope unknown in reviewed evidence.Why unknown

WuXi Biologics Worcester

single-use biologics drug substance manufacturingprotein/mammalian expression not specified · Scope limits · Source ↗

Catalent Madison & Bloomington

mammalian cell line technology (GPEx) and development/manufacturing for new biological entities and biosimilarsApr 2021 release; current ops unconfirmed · Scope limits · Source ↗

AGC Biologics Seattle

Seattle-specific GMP mammalian manufacturing and cell-line development.Named-site claim; molecule-specific suite fit and availability unknown. Source & date

Avid Bioservices Costa Mesa

CHO/HEK293 cell-line and DNA-to-IND process development.Facility development scope; manufacturing train and volume remain unknown. Source & date

Costa Mesa: early phase. Tustin: clinical and commercial manufacturing.Separate campuses; confirm the transfer and manufacturing locations in the proposal. Source & date

Curia (US facilities)

antibodies, proteins, enzymes, and mRNA; stable mammalian cell line developmentScope limits · Source ↗

Vendor capability wording is a starting point for qualification; it is not independent evidence of process performance, GMP status, or molecule fit.

Site scope boundaries from reviewed evidence

See the full qualification checklist →

← Return to the site comparison

New facility pages settle three scope questions

A named-site statement is more useful than a network-wide capability list.

AGC Seattle · mammalian scope

AGC’s Seattle facility page explicitly identifies GMP mammalian manufacturing and mammalian cell-line development at Seattle.

This resolves the earlier network-versus-site gap for broad mammalian scope. Molecule-specific suite fit and open slots still need confirmation. Source & date

Fujifilm Holly Springs · mAbs

Fujifilm’s July 8, 2026 announcement describes Holly Springs as commercial-scale mammalian cell culture manufacturing and says it makes monoclonal antibodies.

This is a vendor manufacturing-scope claim. Participation in FDA PreCheck does not establish product approval or a clean inspection. Source & date

Avid Costa Mesa · development

Avid’s Costa Mesa page documents CHO and HEK293 cell-line development, alongside process, analytical and formulation development for DNA-to-IND programs.

Development host capability does not establish the exact host, vessel train or commercial manufacturing scope for your program. Source & date

Avid identifies Costa Mesa as its early-phase campus and Tustin as the campus for clinical and commercial manufacturing.

Do not apply Avid’s commercial company-wide claim to Costa Mesa. The transfer plan and each site’s manufacturing role still need a written proposal. Source & date